Vantage logo

Close encounters of the Serd kind

All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?

Vantage logo

No Ameera glory for Sanofi

Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?

Vantage logo

Delays hit Sanofi

The Ameera-3 readout gets pushed back again, while fitusiran’s filing will not happen until 2024.